Component
Apoptosis in human HeLa cervical cancer cells
Experimental species, exposure and limitations are retained on each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.
Experimental context and source evidence
- dose
- Indicaxanthin 60 micromolar with cisplatin 10 micromolar; individual-agent controls
- duration
- 24 h
- evidence_access
- Primary open full text, relevant results/methods and PubMed metadata.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Human HeLa cervical cancer cells
- limitations
- Cell-culture chemosensitization is not clinical cancer efficacy. Redox-probe signals and protein changes do not prove direct target binding.
- nutrient_topic
- Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved. · Indicaxanthin
- organism
- Human HeLa cervical cancer cells
- plain_language
- Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.
- primary_references
- The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994
- route
- In vitro co-treatment
- tissue
- Cell death and redox assays
Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 283–292
Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text. · supports · Human HeLa cervical cancer cells · source_derived_draft · unverified_draft
## indicaxanthin-cisplatin-apoptosis Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone. Model/species: Human HeLa cervical cancer cells Tissue: Cell death and redox assays Exposure: Indicaxanthin 60 micromolar with cisplatin 10 micromolar; individual-agent controls Route: In vitro co-treatment Duration: 24 h Limits: Cell-culture chemosensitization is not clinical cancer efficacy. Redox-probe signals and protein changes do not prove direct target binding. Primary reference: The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994 Access: Primary open full text, relevant results/methods and PubMed metadata.
Complete structured claim and evidenceN-acetylcysteine pretreatment reduced apoptosis caused by the indicaxanthin/cisplatin combination in HeLa cells.
Experimental context and source evidence
- dose
- N-acetylcysteine 2 mM before indicaxanthin 60 micromolar plus cisplatin 10 micromolar
- duration
- NAC 1 h before the 24 h combination exposure
- evidence_access
- Primary open full text, relevant results/methods and PubMed metadata.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Human HeLa cervical cancer cells with NAC pretreatment
- limitations
- NAC blunted the combination response without restoring every outcome to baseline. This experiment is not a recommendation for or against NAC during chemotherapy.
- nutrient_topic
- Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved. · Indicaxanthin
- organism
- Human HeLa cervical cancer cells with NAC pretreatment
- plain_language
- N-acetylcysteine pretreatment reduced apoptosis caused by the indicaxanthin/cisplatin combination in HeLa cells.
- primary_references
- The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994
- route
- In vitro pretreatment/co-treatment
- tissue
- Cell death and redox assays
Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 327–336
Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text. · supports · Human HeLa cervical cancer cells with NAC pretreatment · source_derived_draft · unverified_draft
## indicaxanthin-nac-combination-antagonism N-acetylcysteine pretreatment reduced apoptosis caused by the indicaxanthin/cisplatin combination in HeLa cells. Model/species: Human HeLa cervical cancer cells with NAC pretreatment Tissue: Cell death and redox assays Exposure: N-acetylcysteine 2 mM before indicaxanthin 60 micromolar plus cisplatin 10 micromolar Route: In vitro pretreatment/co-treatment Duration: NAC 1 h before the 24 h combination exposure Limits: NAC blunted the combination response without restoring every outcome to baseline. This experiment is not a recommendation for or against NAC during chemotherapy. Primary reference: The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994 Access: Primary open full text, relevant results/methods and PubMed metadata.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.